Compare ACADIA Pharmaceuticals Inc. (ACAD) vs VNET Group Inc (VNET) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs VNET Group Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while VNET Group Inc trades at $8.3 (market cap $2.19B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 2.1× VNET Group Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | VNET | |
|---|---|---|
Market Cap | $4.49B | $2.19B |
Sector | Health | Technology |
52-Week High | $28.06 | $14.03 |
52-Week Low | $20.06 | $6.97 |
Enterprise Value | $3.69B | $5.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
VNET trades at $7.81, down 1.39% today, amid bearish technical signals and recent earnings misses. The stock shows negative profitability with a -21.63% net income margin and -43.21% ROE for 2025, though revenue reached $9.95B. Analyst sentiment remains positive with 62.5% buy ratings, pointing to a 54% upside target. Recent news highlights strategic AI investments and leadership changes, while a class action settlement adds legal overhang.
The outlook is mixed: strong revenue growth and AI demand offer upside, but persistent losses and high debt pose risks. Investors should weigh analyst optimism against fundamental weaknesses and legal uncertainties before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
